Skip to main content

amjevita

Generic: ADALIMUMAB-ATTO

amjevita: developed by 1 company · 1 FDA decision.

amjevita evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect amjevita to AMGN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could amjevita → AMGN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (1)
CompanyPhase
AMGEN INC (AMGN)Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inh(AMGN)FDA ↗
BLA761024Type 2 New Active Ingredient and Type 4 New CombinationStandardOtherInjectable

Frequently asked questions

Who is developing amjevita?

amjevita is being developed by AMGEN INC.

What is amjevita's latest FDA decision?

The most recent tracked FDA decision for amjevita is Approval for 1 INDICATIONS AND USAGE AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inh, dated September 23, 2016.